Person-checked company records fromPerson-checked records $750See a worked exampleHuman review in progress

Talk to sales

KeptIndex

Executive Record

Stephen R. Davis

Chief executive: Acadia Pharmaceuticals Inc. (before 2014 to 23 Sep 2024)

12commitments announced
12with a clear outcome
7met on time
–rate shown after 15 outcomes

Commitments are credited to the chief executive in office on the day they were announced. Where a deadline fell after the leader left, the entry is marked. Sources for each leadership change: Acadia Pharmaceuticals Inc. filing.

Commitments announced under Stephen R. Davis

Acadia Pharmaceuticals Inc.announced 27 Feb 2024 Announce top-line results from the ADVANCE-2 study of pimavanserin Met31 Mar 2024
Acadia Pharmaceuticals Inc.announced 2 Aug 2023 Initiate a Phase 2/3 program for ACP-204 in Alzheimer’s disease psychosis Met31 Dec 2023
Acadia Pharmaceuticals Inc.announced 2 Aug 2023 Initiate a Phase 3 trial of ACP-101 for Prader-Willi syndrome Met31 Dec 2023
Acadia Pharmaceuticals Inc.announced 28 Feb 2022 Submit an NDA for trofinetide for the treatment of Rett syndrome Late30 Jun 2022
Acadia Pharmaceuticals Inc.announced 28 Feb 2022 Complete enrollment in the pivotal ADVANCE-2 study for pimavanserin Late31 Dec 2022
Acadia Pharmaceuticals Inc.announced 28 Feb 2022 Deliver results from two Phase 2 studies for ACP-044 Partly met31 Dec 2022
Acadia Pharmaceuticals Inc.announced 21 Dec 2021 Resubmit the supplemental New Drug Application for pimavanserin Met31 Mar 2022
Acadia Pharmaceuticals Inc.announced 6 Dec 2021 Submit a New Drug Application for trofinetide Late30 Jun 2022
Acadia Pharmaceuticals Inc.announced 8 Nov 2021 Report top-line results from the Phase 3 LAVENDER study Met31 Dec 2021
Acadia Pharmaceuticals Inc.announced 8 Nov 2021 Report top-line results from the Phase 2 study of ACP-044 Late31 Mar 2022
Acadia Pharmaceuticals Inc.announced 24 Feb 2021 Initiate the bunionectomy Phase 2 study of ACP-044 for acute pain Met31 Mar 2021
Acadia Pharmaceuticals Inc.announced 24 Feb 2021 Initiate the osteoarthritis Phase 2 study of ACP-044 Met30 Jun 2021

Is this record wrong, or are you Stephen R. Davis? Add a statement or ask for a correction.

The Deadline Report

One email a week: the corporate commitments that came due, which were met, which slipped, and what is due next. Free. Stop any time.

No advertising. We never sell or share your address.